of this Current Report on Form 8-K and the related information in Exhibits 99.1 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…

Chief Technology Officer — Girish Venkatachaliah: Mr. Venkatachaliah's employment with the company will terminate effective August 1, 2026.

of this Current Report on Form 8-K and the related information in Exhibits 99.1 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…

Chief Executive Officer and President — Tim O’Rourke: Tim O'Rourke was hired as the new CEO and President of agilon health, inc.

Material Modifications to Rights of Security Holders. To the extent required by Item 3.03, the disclosure set forth in

Results of Operations and Financial Condition. On February 25, 2026 , agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above under

Entry into a Material Definitive Agreement. On February 12, 2026 (the “Third Amendment Effective Date”), agilon health, inc. (the "Company"), agilon health management, inc. (f/k/a agilon health, inc.) (the “Management”) and Agilon Health Intermediate Holdings, Inc. (“Holdings”), entered into the Third Amendment (the “Amendment”) to the Credit Agreement, dated as of February 18, 2021 (as previously amended by the First Amendment to the Credit Agreement, dated as of March 1, 2021, and the Secon…

Jeffrey Schwaneke: Amended Employment Agreement with Jeffrey Schwaneke, CFO and Executive Vice President.

Regulation FD Disclosure. As required by Section 802.01C of the NYSE Listed Company Manual, the Company issued a press release on November 7, 2025, announcing that it had received the notice of noncompliance with the NYSE’s continued listing standard. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including the information contained in Exhibit 99.1 of this Current Report on Form 8-K, is being furnished herewith and shall not be deemed “fi…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 5, 2025, agilon health, inc. (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) informing the Company that it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ended N…

Results of Operations and Financial Condition. On November 4, 2025, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Results of Operations and Financial Condition. On August 4, 2025, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Chief Executive Officer and President — Mr. Steven J. Sell: Mr. Steven J. Sell resigned as CEO and President without a named successor.

Results of Operations and Financial Condition. On May 6, 2025, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three months ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Results of Operations and Financial Condition. On February 25, 2025 , agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Entry Into a Material Definitive Agreement. On December 4, 2024, agilon health, inc. (the “Company”) began entering into new forms of indemnification agreements with the Company’s directors, executive officers, and certain other officers (each, an “Indemnitee”). The indemnification agreements provide, among other things, that, subject to certain exclusions, the Company will indemnify an Indemnitee to the fullest extent permitted by applicable law and the Company’s Amended and Restated Certifi…

Results of Operations and Financial Condition. On November 7, 2024, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and nine months ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

of this Current Report on Form 8-K and the related information in Exhibit 99.1 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…

Chief Financial Officer and Executive Vice President — Jeff Schwaneke: The company appointed a new Chief Financial Officer and Executive Vice President from an external hire.

of this Current Report on Form 8-K and the related information in Exhibit 99.1 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…

Results of Operations and Financial Condition. On February 27, 2024 , agilon health, inc. (“agilon” or the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Chief Medical Officer (CMO) — Benjamin Kornitzer, M.D.: Dr. Benjamin Kornitzer is departing his role as CMO and transitioning to a strategic advisory role.

Results of Operations and Financial Condition. On January 5, 2024, agilon health, inc. (“agilon health”) issued a press release updating its full year 2023 guidance, providing its initial outlook for 2024 and withdrawing its 2026 outlook. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

CFO — Timothy Bensley: Timothy Bensley intends to retire from his position as CFO, with a planned transition and search for a new CFO.